Overview

A Multi-center, Placebo-controlled Study to Evaluate NT100 in Pregnant Women With a History of Unexplained Recurrent Pregnancy Loss (RPL)

Status:
Unknown status
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
This is a randomised, double blind, multi-center, placebo-controlled study of subcutaneous NT100 in pregnant women with a history of unexplained recurrent pregnancy loss. Approximately 150 participants will be randomised to receive subcutaneous NT100 or placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Nora Therapeutics, Inc.